Why did MSB rise 23.4% on 29 Oct 2026?
Mesoblast · Pharmaceuticals, Biotechnology & Life Sciences
$10,000 in MSB shares rose to $12,340 that day. It was up as much as 26.6% during the day: about 10 times a usual day's move for MSB, with twice the usual shares traded.
Mesoblast released a market-sensitive quarterly activities and cash flow report that appears to have contained positive news, driving the stock up over 20%.
$10,000 in ISO, the ETF that holds the most MSB, gained ▲ $18 that day. In IOZ it was a gain of $2. 17 ETFs hold MSB ›
An ETF is one investment, bought on the stock exchange, that holds many companies at once.
The news
We found no news articles for this move. Headlines link to the publisher.
How the model got there ›
The only stock-specific catalyst is the market-sensitive Quarterly Activities/Appendix 4C Cash Flow Report released at 22:54 UTC on 28 October, approximately 3 hours before detection — timing and sensitivity flag align well with the price move. No other Layer 2 signals are proportionate: the same-industry peers' median move was just 2.06% and the ASX Healthcare sector index (^AXHJ) moved only 0.70%, both far below the 20.21% move, ruling out sector_flow. The ASX 200 moved only 0.29%, ruling out macro/market-wide explanations. The announcement is categorised as a quarterly activities report (not a formal earnings result), so operational_update is the best-fit taxonomy category, though positive cash flow or clinical/business progress within the report is the probable catalyst; confidence is medium rather than high because the full content of the report is not available to confirm the specific positive element.
Company announcements
Quarterly Activities/Appendix 4C Cash Flow Report
Commitments Test Entity - First Quarter Activity Report · 29 Oct 2026 · market sensitive
Markets that moved with it · 4
Markets that tend to move with this stock, on the same day or the day before.
- S&P 500A market it earns in · the day beforesame direction+0.28%
- Nikkei 225A market it earns in · the day beforesame direction+1.08%
- ASX 200 Health CareIts sector · same daysame direction+0.70%
- US dollar / Chinese yuanA market it earns in · the day beforeother way−0.16%
MSB before and after
Mesoblast: price and every explained moveWhat $10,000 in each ETF gained that day
$77 of every $10,000 in ISO was Mesoblast; it rose 23.4%, so $10,000 in ISO gained $18.
- ISO iShares S&P/ASX Small Ordinaries ETF$77 of every $10,000 was Mesoblast▲ $18
- SSO STATE STREET SPDR S&P/ASX SMALL ORDINARIES ETF$76 of every $10,000 was Mesoblast▲ $18
- FAIR BetaShares Australian Sustainability Leaders ETF$49 of every $10,000 was Mesoblast▲ $11
- VSO Vanguard MSCI Australian Small Companies Index ETF$31 of every $10,000 was Mesoblast▲ $7
- OZXX Global X Australia ex Financials & Resources ETF$30 of every $10,000 was Mesoblast▲ $7
- IOZ iShares Core S&P/ASX 200 ETF$8 of every $10,000 was Mesoblast · a widely held fund▲ $2
- A200 BetaShares Australia 200 ETF$7 of every $10,000 was Mesoblast · a widely held fund▲ $2
- VAS Vanguard Australian Shares Index ETF$7 of every $10,000 was Mesoblast · a widely held fund▲ $2
9 more ETFs ›
- EX20 BetaShares Australian Ex-20 Portfolio Diversifier ETF$21 of every $10,000 was Mesoblast▲ $5
- GEAR BetaShares Geared Australian Equities Complex ETF$17 of every $10,000 was Mesoblast▲ $4
- VETH Vanguard Ethically Conscious Australian Shares ETF$9 of every $10,000 was Mesoblast▲ $2
- STW STATE STREET SPDR S&P/ASX 200 ETF$8 of every $10,000 was Mesoblast▲ $2
- AYLD Global X S&P/ASX 200 Covered Call Complex ETF$8 of every $10,000 was Mesoblast▲ $2
- AUST BetaShares Managed Risk Australian Shares Complex ETF$8 of every $10,000 was Mesoblast▲ $2
- A300 Global X Australia 300 ETF$7 of every $10,000 was Mesoblast▲ $2
- ROYL BetaShares Global Royalties ETF$7 of every $10,000 was Mesoblast▲ $2
- VGE Vanguard FTSE Emerging Markets Shares ETFunder $1 of every $10,000 was Mesoblastunder $1